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Gonadotropin-releasing hormone (GnRH) antagonists, which became commercially available from 1999, have been
used for the prevention of premature luteinizing hormone (LH) surges in controlled ovarian stimulation for in vitro
fertilization or intracytoplasmic sperm injection. This review focuses on the recent literature on the use of GnRH
antagonists and provides guidelines for optimal use in light of increasing evidence showing that GnRH antagonists
are safe and effective, allowing flexibility of treatment in a wide range of patient populations. This includes patients
undergoing first-line controlled ovarian stimulation, poor responders, and women diagnosed with polycystic ovary
syndrome. The GnRH antagonist offers a viable alternative to the long agonists, providing a shorter duration of
treatment with fewer injections and with no adverse effects on assisted reproductive technology outcome. This
results in a significantly lower amount of gonadotropins required, which is likely to lead to improved patient
compliance.
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Gonadotropins were first introduced in the early 1960s
and have been used in ovarian stimulation cycles to induce
multiple follicular development, particularly during the
past 3 decades, in women undergoing in vitro fertilization
(IVF) treatment. Gonadotropin-releasing hormone (GnRH)
analogs are administered along with gonadotropins to pre-
vent the occurrence of a surge in luteinizing hormone
(LH), which may occur prematurely before the leading
follicle reaches the optimum diameter (≥17 mm) for trig-
gering ovulation by human chorionic gonadotropin (hCG)
injection. Without the use of GnRH analogs, LH surges
would occur in approximately 20% of stimulated IVF pa-
tients [1,2]. Preventing LH surges using GnRH analogs im-
proves oocyte yield with more embryos, allowing better
selection and, therefore, leading to an increase in preg-
nancy rates [3].
Since the early 1980s, the use of GnRH agonists in
ovarian stimulation has greatly improved the success
rate of IVF [4]. GnRH agonists reduce the incidence of
premature LH surges [5,6] by suppressing gonadotropin* Correspondence: acopperman@rmaofny.com
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short period of gonadotropin hypersecretion. More re-
cently, GnRH antagonists with high potency and fewer
side effects have been introduced into IVF and have
emerged as an alternative in preventing premature LH
surges. Unlike GnRH agonists, these potent GnRH an-
tagonists cause immediate, rapid gonadotropin suppres-
sion by competitively blocking GnRH receptors in the
anterior pituitary gland, thereby preventing endogenous
GnRH from inducing LH and follicle-stimulating hor-
mone (FSH) release from the pituitary cells. Further-
more, GnRH antagonist suppression of gonadotropin
secretion can be quickly reversed [7-9]. This different
pharmacologic mechanism of action makes GnRH an-
tagonists a more logical choice to use in IVF for the pre-
vention of premature LH surges [5].
Ganirelix (Orgalutran, N.V. Organon, Oss, The
Netherlands) and cetrorelix (Cetrotide, Serono Inter-
national S.A., Geneva, Switzerland) are subcutaneously
administered GnRH antagonists approved for clinical use
in IVF therapy [10,11]. Since 1999, GnRH antagonists have
been used for the prevention of premature LH surges in
women undergoing controlled ovarian stimulation for
IVF. Clinically, stimulation with urinary FSH or recombin-
ant human FSH (rFSH), either alone or in combinationoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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(hMG), is started on day 2 or 3 of the menstrual cycle and
the GnRH antagonist is administered in the late follicular
phase, from day 5 or 6 of stimulation onward. The dose of
gonadotropins may be adjusted according to individual re-
sponse. Both gonadotropins are continued daily until two
to three follicles reach ≥17 mm in diameter (on ultrasound
assessment) at which time hCG is administered to induce
final oocyte maturation (Figure 1). This review focuses on
literature concerning the use of GnRH antagonists in ovar-
ian stimulation for IVF and provides guidelines for optimal
use.
Potential advantages of GnRH antagonist protocols
There are a number of theoretical advantages of GnRH
antagonists versus GnRH agonists [12,13], including a
shorter duration of injectable drug treatment, absence of
vasomotor symptoms, less risk of inadvertent administra-
tion during early pregnancy, avoidance of ovarian cyst for-
mation, and a significantly smaller dose of gonadotropin
per cycle, which translate to improved patient convenience
[9,14]. The literature regarding the cost effectiveness of
GnRH antagonist protocols is currently contradictory. In a
randomized trial by Badrawi et al. [15], the cost of medica-
tion per cycle and per pregnancy was shown to be higher
in a GnRH antagonist protocol than a GnRH agonist
protocol, while an observational study by Kamath et al.
[16] found costs of the two protocols to be similar.
Current evidence suggests that GnRH antagonists and
agonists are similarly effective in the context of oocyte
donation [17]. However, due to their increased conveni-
ence, GnRH antagonist protocols are often the regimen
of choice for oocyte donors. More recently, it has been
recommended that treatment guidelines for the preven-
tion of ovarian hyperstimulation syndrome (OHSS) [18]
should be updated to incorporate findings from the lit-
erature over the past 5 years. The literature shows that
GnRH antagonist protocols and GnRH agonist triggering
of final oocyte maturation, especially when used inFigure 1 Schematic presentation of the ganirelix treatment regimen.combination, may reduce OHSS and have considerable
promise in preventing OHSS [19].
Potential disadvantages of GnRH antagonist protocols
Potential disadvantages of GnRH antagonist protocols
over GnRH agonist protocols include less flexible options
in terms of cycle programming and early studies sug-
gesting a minor reduction in pregnancy rates per cycle
[20,21]. Increasing flexibility of GnRH antagonist proto-
cols can be achieved with oral contraceptives [20]. Pre-
treatment with oral contraceptives allows programming of
cycles, whereby stimulation can be started during a 5-day
interval following withdrawal of the oral contraceptive
[22]. Use of oral contraceptives with a GnRH antagonist
protocol and the pregnancy outcomes of GnRH antagonist
protocols are discussed below.
Pregnancy outcomes of GnRH antagonist protocols
Despite an initial trend toward a lower pregnancy rate
with GnRH antagonists compared with agonists in a
number of early randomized controlled studies, a meta-
analysis by Kolibianakis et al. [23] and a review by Tur-
Kaspa and Ezcurra [24] found no significant difference
in the probability of live birth rates with the use of either
a GnRH agonist or antagonist protocol [23] (Table 1).
In normal responders, the use of GnRH antagonist ver-
sus long GnRH agonist protocols was associated with a
statistically significant reduction of OHSS, with no evi-
dence of a difference in live birth rates [45]. GnRH antag-
onist protocols have been shown to result in better
outcomes than GnRH agonists in patients with poor prog-
nosis [52,53]. In a meta-analysis of six clinical trials com-
paring GnRH antagonist versus GnRH agonist protocols
in poor ovarian responders in IVF/intracytoplasmic sperm
injection (ICSI) cycles Franco et al. [54] indicated no dif-
ference between GnRH antagonists and agonists with
respect to cycle cancellation rate, number of mature oo-
cytes, and clinical pregnancy rate per cycle initiated, per
oocyte retrieval, and per embryo transfer. Al-Inany et al.
Table 1 Results of meta-analyses of GnRH analogs among patients treated for IVF – odds ratio of live birth rate
GnRH antagonists GnRH agonists Weight Odds ratio (95% CI)
Events Total Events Total
RCTs included in Kolibianakis et al. [23]
Albano 2001 [25] 34 198 19 95 0.83 (0.44-1.55)
European 2000 [8] 97 486 61 244 0.75 (0.52–1.08)
Olivennes 2000 [26] 22 126 9 43 0.80 (0.34–1.90)
N American 2001 [27] 60 208 36 105 0.78 (0.47–1.28)
Middle East 2001 [28] 72 236 37 119 0.97 (0.60–1.57)
Akman 2001 [29] 4 24 5 24 0.76 (0.18–3.26)
Hohmann 2003 [30] 18 111 10 58 0.93 (0.40–2.17)
Martinez 2003 [31] 4 21 3 23 1.57 (0.31–8.01)
Franco 2003 [32] 3 14 2 6 0.55 (0.07–4.56)
Hwang 2004 [33] 8 27 8 29 1.11 (0.35–3.53)
Sauer 2004 [34] 9 24 9 25 1.07 (0.33–3.41)
Loutradis 2004 [35] 9 58 12 58 0.70 (0.27–1.63)
Check 2004 [36] 8 30 5 30 1.82 (0.52–6.38)
Xavier 2005 [37] 7 66 8 65 0.85 (0.29–2.48)
Malmusi 2005 [38] 5 30 5 30 1.00 (0.28–3.89)
Marci 2005 [39] 4 30 0 30 10.38 (0.53–201.45)
Cheung 2005 [40] 3 33 2 33 1.55 (0.24–9.94)
Barmat 2005 [41] 13 40 17 40 0.65 (0.26–1.62)
Bahceci 2005 [42] 29 73 33 75 0.84 (0.44–1.61)
Badrawi 2005 [15] 11 50 13 50 0.80 (0.32–2.02)
Schmidt 2005 [43] 3 24 3 24 1.00 (0.18–5.53)
Lee 2005 [44] 13 41 8 20 0.70 (0.23–2.11)
Total (n = 22) 436 1950 305 1226 0.86 (0.72–1.02)
RCTs included in Al-Inany et al. [45]
All women
Albano 2000 [25] 34 198 19 95 13.5% 0.83 (0.44–1.55)
Barmat 2005 [41] 13 40 17 40 7.3% 0.65 (0.26–1.62)
Heijnen 2007 [46] 70 205 78 199 33.0% 0.80 (0.54–1.21)
Hurine 2006 [47] 17 91 17 91 8.8% 1.00 (0.47–2.11)
Kim 2009 [48] 13 54 8 28 5.1% 0.79 (0.28–2.22)
Kurzawa 2008 [49] 14 37 18 37 7.1% 0.64 (0.25–1.62)
Lin 2006 [50] 22 60 21 60 8.4% 1.08 (0.51–2.27)
Marci 2005 [39] 4 30 0 30 0.3% 10.36 (0.53–201.45)
Ye 2009 [51] 35 109 39 111 16.6% 0.87 (0.50–1.53)
Subtotal (95% CI) 824 691 100.0% 0.86 (0.69–1.08)
Total events 222 217
Heijnen 2007 [46] 70 205 78 199 79.7% 0.80 (0.54–1.21)
Lin 2006 [50] 22 60 21 60 8.4% 1.08 (0.51–2.27)
Subtotal (95% CI) 265 259 100.0% 0.89 (0.62–1.26)
Total events 97 102
Heterogeneity: χ2 = 0.32, df = 1 (P = 0.57)
Test for overall effect: Z = 0.66 (P = 0.51)
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Table 1 Results of meta-analyses of GnRH analogs among patients treated for IVF – odds ratio of live birth rate
(Continued)
Cetrorelix only
Albano 2000 [25] 34 198 19 95 26.3% 0.83 (0.44–1.55)
Hurine 2006 [47] 17 91 17 91 17.1% 1.00 (0.47–2.11)
Kim 2009 [48] 13 54 8 28 9.9% 0.79 (0.28–2.22)
Kurzawa 2008 [49] 14 37 18 37 13.8% 0.64 (0.25–1.62)
Marci 2005 [39] 4 30 0 30 0.5% 10.36 (0.53–201.45)
Ye 2009 [51] 35 109 39 111 32.4% 0.87 (0.50–1.53)
Subtotal (95% CI) 519 392 100.0% 0.89 (0.65–1.23)
Total events 97 102
Heterogeneity: χ2 = 3.31, df = 5 (P = 0.65)
Test for overall effect: Z = 0.70 (P = 0.49)
Ganirelix only
Barmat 2005 [41] 13 40 17 40 100.0% 0.65 (0.26–1.62)
Subtotal (95% CI) 40 40 100.0% 0.65 (0.26–1.62)
Total events 97 102
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.36)
Adapted from Kolibianakis 2006 [23] and Al-Inany 2011 [45].
GnRH = gonadotropin-releasing hormone; IVF = in vitro fertilization.
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GnRH antagonist and agonist protocols in a recent
Cochrane review.
In oocyte donation [55] and embryo transfer [56] cycles,
the replacement of GnRH agonist with a GnRH antagonist
had no impact on the pregnancy and implantation rates.
Higher pregnancy rates were also shown in a gonado-
tropin intrauterine insemination cycle than in a cycle
where no intervention took place [57]. In a prospective
randomized trial, Prapas et al. [58] reported that GnRH
antagonist administration during the proliferative phase
did not adversely affect endometrial receptivity in oocyte
recipients.
Optimal use of GnRH antagonists in diverse treatment
situations
First-line treatment
GnRH antagonists have been shown to be an effective
treatment in women undergoing controlled ovarian sti-
mulation for IVF in multiple meta-analyses and clinical
studies. In the systematic review and meta-analyses by
Kolibianakis et al. [23], it was shown that the probability
of live birth was not dependent on the type of GnRH ana-
log used for the suppression of premature LH rises (odds
ratio 0.86; 95% confidence interval 0.72-1.02). In a more
recent systematic review, Al-Inany et al. [45] also reported
that there was no significant difference in live birth rates
following a GnRH antagonist or GnRH agonist protocol
(odds ratio 0.86, 95% confidence interval 0.69-1.08).In a retrospective review of patients with good prognosis
undergoing their first IVF cycle, Johnston-MacAnanny
et al. [59] showed that clinical and ongoing pregnancy
rates and implantation rates were similar in 755 good re-
sponder patients undergoing a GnRH agonist protocol
and 378 good responder patients undergoing a GnRH an-
tagonist protocol during their first cycle of IVF. Borm and
Mannaerts [8] evaluated the efficacy and safety of ganirelix
in 730 women undergoing ovarian stimulation with rFSH.
The patients were randomized in a 2:1 ratio to either 0.25
mg ganirelix or buserelin (the trial was designed as a
noninferiority study using a long protocol of intranasal
buserelin and rFSH as a reference treatment). Ganirelix in
comparison with buserelin resulted in a shorter duration
of treatment (5 vs 26 days). Comparison of the number
and size of follicles indicated that in the ganirelix group,
the final number of follicles on the day of hCG adminis-
tration, was smaller (10.7 vs 11.8) and produced less peak
estradiol concentration (1190 vs 1700 pg/ml) than the
buserelin group. The ganirelix regimen resulted in the re-
covery of good-quality oocytes, as reflected by the high
fertilization rate (62.1%), and a similar number of good-
quality embryos (3.3), as the reference group (3.5). The
clinical outcome (defined as the ongoing pregnancy rate
per attempt) was good (20.3%), although pregnancy rates
were found to be slightly higher in the reference group
(25.7%). Interestingly, the ongoing pregnancy rate per at-
tempt for patients treated at study sites (n = 10) that had
previous experience with the ganirelix regimen was
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the buserelin group. This suggests that the slightly lower
pregnancy rates observed in early trials may have been re-
lated to lack of experience with the use of antagonist pro-
tocols. With regard to safety, ganirelix was found to be
safe and well tolerated with a two-fold lower (2.4%) inci-
dence of OHSS than was found in the buserelin (5.9%)
group. Overall, the study demonstrated that ganirelix pro-
vides a safe, short, and convenient treatment option for
patients undergoing controlled ovarian hyperstimulation
for IVF/ICSI and results in good clinical outcome.
Second-line treatment (treatment of poor responders)
GnRH antagonists have been used effectively in patients
who have a poor prognosis or who have shown a dimin-
ished ovarian response to controlled ovarian stimulation.
In the systematic review and meta-analyses by Kolibianakis
et al. [23], it was shown that the probability of live birth in
poor responders was not dependent on the type of GnRH
analog used for the suppression of premature LH rises
(odds ratio 1.34; 95% confidence interval 0.70-2.59). In a
more recent systematic review, Al-Inany et al. [45] also
reported no significant differences in clinical pregnancy
rates in poor responders following a GnRH antagonist and
GnRH agonist protocol (odds ratio 0.71, 95% confidence
interval 0.49-1.02).
Schmidt et al. [43] showed that the use of GnRH an-
tagonists was as effective as the conventional microdose
protocol and that embryo quality, implantation rates,
and ongoing pregnancy rates were comparable in a ran-
domized prospective study comparing ganirelix with a
microdose GnRH agonist in patients with poor ovarian
response. The microdose flare protocol has been proven
to increase both clinical and ongoing pregnancy rates in
poor responders. The authors concluded that the
ganirelix protocol may be preferable because it requires
significantly fewer injections and a shorter treatment
course, resulting in cost savings and improved conveni-
ence for the patient. An earlier review by Copperman
[60] also noted that the use of a GnRH antagonist for
the suppression of premature LH surges in poor re-
sponders is at least as good as the microdose flare and
provides better cycle outcomes than the long luteal
leuprolide acetate downregulation protocols.
The use of GnRH antagonists among patients with poor
prognosis was also evaluated by Shapiro et al. [12] in a
nonrandomized, noncontrolled, retrospective review of 204
patients (165 cycles in patients with a normal IVF progno-
sis and 60 cycles in those with a poor prognosis). Overall,
the pregnancy rates per initiated cycle and per embryo
transfer were 33.3% and 42.1%, respectively, with a cycle
cancellation rate of 21%. The patients with poor prognosis
had a pregnancy rate of 8.3% per attempt and 15% per
transfer compared with 40% and 45%, respectively, inpatients with normal prognosis. While this retrospective
analysis supports the use of GnRH antagonist protocols as
an alternative to agonist protocols in normal responders,
the use of GnRH antagonists in patients with poor IVF
prognosis resulted in predictably poor outcomes.
In a recent meta-analysis comparing the efficacy of
GnRH antagonists versus agonists in poor responders, Pu
et al. [61] showed that GnRH antagonists resulted in a
shorter duration of stimulation, but there was no differ-
ence in the number of oocytes retrieved, the cycle can-
cellation rate, or the clinical pregnancy rate.
The ability to offer patients who have suffered numerous
failed cycle attempts a choice of effective alternatives may
improve outcomes for these women. Currently, in many
centers, the luteal phase estradiol patch/GnRH antagonist
(LPG) protocol is the treatment of choice for women with
a poor response to ovarian stimulation. This protocol in-
volves administration of transdermal estradiol patches and
a GnRH antagonist in the luteal phase of the preceding
menstrual cycle, followed by high-dose follicular phase go-
nadotropin stimulation with adjunctive GnRH antagonist.
Dragisic et al. [62] first described this novel protocol in
2005 and demonstrated that it improved ovarian respon-
siveness among poor responders, with more uniform
follicular development, more oocytes retrieved, higher
number of transferred embryos, and improved pregnancy
rates. Weitzman et al. [63] retrospectively compared the
outcomes of patients with a history of failed cycles who
had undergone ovarian stimulation with either an LPG
protocol (n = 45) or a microdose agonist protocol (n = 76)
over a 1-year period [63]. All clinical outcomes, including
ongoing pregnancy rates, were comparable between the
two groups, suggesting that the use of an LPG protocol is
at least as effective as a microdose agonist protocol. Simi-
lar findings were obtained by the same group of investiga-




Cetrorelix acetate, a US Food and Drug Administration-
approved GnRH antagonist, has been shown to be ef-
fective and safe as a single-dose (3 mg) or multiple-dose
regimen (0.25 mg daily) [65,66]. In a prospective ran-
domized trial, Vlaisvljevic et al. [67] showed that 3 mg
cetrorelix had comparable efficacy to the GnRH agonist
goserelin. However, multiple-dose protocols are now the
standard and single-dose protocols are rarely used.
Multiple dose
Ganirelix is only available as a multiple-dose regimen.
The multiple-dose protocol for ganirelix involves the ad-
ministration of 0.25 mg daily from day 6 or 7 of stimula-
tion, or when the leading follicle is 14–15 mm, until
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Study [69] was the first multicenter, double-blind, ran-
domized dose-finding study to establish the minimal ef-
fective dose of ganirelix to prevent premature LH surges
in 333 women undergoing ovarian stimulation with rFSH.
Six different ganirelix doses (0.0652, 0.125, 0.25, 0.5, 1.0,
and 2.0 mg/0.5 ml) were administered daily by subcutane-
ous injection. In this study, patients were treated with a
fixed dose of 150 IU rFSH for 5 days before starting
ganirelix. The study revealed that 0.25 mg/d was the min-
imal effective dose with regard to preventing LH surges
and resulted in a good clinical outcome with an ongoing
pregnancy rate of 34% per attempt and 37% per transfer.
Administration of 0.25 mg daily ganirelix has been shown
to be safe and effective in the prevention of premature LH
surge in further studies [8,27,28].
The North American Ganirelix Study Group adminis-
tered this GnRH antagonist to 313 patients for whom
controlled ovarian hyperstimulation and IVF/ICSI were
indicated [27]. Patients received one controlled ovarian
hyperstimulation cycle with ganirelix or a long protocol
of leuprolide acetate in conjunction with rFSH [27].
From day 6 of rFSH treatment, ganirelix (0.25 mg) was
administered daily up to and including the day of hCG
administration. The mean number of oocytes retrieved
per attempt was 11.6 in the ganirelix group and 14.1 in
the leuprolide group. Fertilization rates were 62.4% and
61.9% and implantation rates were 21.1% and 26.1% in
the ganirelix and leuprolide groups, respectively. Clinical
and ongoing pregnancy rates per attempt, respectively,
were 35.4% and 30.8% in the ganirelix group and 38.4%
and 36.4% in the leuprolide acetate group. Fewer moder-
ate and severe injection-site reactions were reported
with ganirelix (11.9% and 0.6%) than with leuprolide
(24.4% and 1.1%).
The European and Middle East Orgalutran Study
Group, compared the use of ganirelix (0.25 mg adminis-
tered from day 6 of rFSH treatment up to and including
the day of hCG administration) with the GnRH agonist
triptorelin (0.1 mg), as a reference treatment in a long
protocol [28]. Overall, the results showed that ganirelix
achieved similar clinical efficacy with a shorter duration
of treatment compared with the GnRH agonist. The
ganirelix regimen was 17 days shorter (9 vs 26 days)
than the triptorelin regimen with a median reduction in
the total dose of rFSH utilized of 450 IU (1350 vs 1800
IU). The fertilization rates and the number of good-
quality embryos were similar in both treatment groups.
The implantation rates of the two treatment arms were
identical (22.9%) with similar ongoing pregnancy rates
(31.0% for ganirelix vs 33.9% for triptorelin). Further-
more, local tolerance of ganirelix appeared to be better
than that of triptorelin, as the percentage of subjects
with at least one local skin reaction was two-fold lowerwhen using the ganirelix regimen (11.9% for ganirelix vs
24.1% for triptorelin).
In a prospective randomized trial in 185 patients under-
going assisted reproductive technologies Wilcox et al. [70]
compared a single injection of cetrorelix (3 mg) with a
daily dose of 0.25 mg of ganirelix in a flexible protocol.
Cetrorelix and ganirelix were found to be equally effective;
no patient in either treatment group had a premature LH
surge and there were no statistically significant differences
between treatments for any IVF/ICSI outcomes, including
pregnancy rates. Cetrorelix is also available as a multiple-
dose regimen (0.25 mg daily). Hsieh et al. [71] reported
that the minimum effective dose of cetrorelix for pituitary
suppression is 0.25 mg, resulting in comparable pregnancy
rates. Olivennes et al. [65] showed that the multiple-dose
regimen of cetrorelix (0.25 mg daily) offers equal efficacy
and safety to the single-dose regimen (3 mg). Similar effi-
cacy and safety results were shown in a cetrorelix (0.25
mg daily) or buserelin protocol [21].
Flexible versus fixed dosing
Flexible dosing was introduced to reduce the number of an-
tagonist injections and the duration of stimulation. It is
recommended that fixed dosing is started from day 5 or 6
of stimulation [72,73] while flexible dosing starts when the
follicles reach a size of >14 mm [74-76]. It has been sug-
gested that development of flexible dosing regimens, that
is, individualizing or tailoring GnRH antagonist adminis-
tration, might lead to better clinical outcomes in GnRH
antagonist-treated patients [77]. Results from several clin-
ical studies support the efficacy and safety of flexible-dosing
regimens with ganirelix, though some show no significant
advantage over the standard fixed-dose regimen [78-80].
Nevertheless, there is evidence that flexible dosing regi-
mens lead to improvement in the outcomes of ovarian
stimulation cycles. In a prospective, randomized, single-
center study comparing fixed multiple-dose antagonist
with a flexible ganirelix regimen, Ludwig et al. [75] showed
an improved outcome when a tailored rather than a stan-
dardized fixed protocol was used to schedule the start of
the GnRH antagonist; a higher yield of oocytes was
achieved despite less rFSH used. There were, however, no
differences in pregnancy rates among the three groups.
The benefits of flexible GnRH antagonist administration
according to follicular size versus starting dosing on a fixed
day were also highlighted by Al-Inany et al. [81] in a meta-
analysis of four randomized trials. Although no statistically
significant difference in pregnancy rate was observed be-
tween flexible and fixed protocols, there was a significant
reduction in the amount of rFSH with the flexible protocol.
Use with GnRH agonist trigger
Ovulation can either be induced with a bolus injection
of hCG or a GnRH agonist. An advantage of using a
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potential reduction in the risk of OHSS [22]. As an ef-
fective alternative to hCG-induced ovulation, GnRH ag-
onists induce a sustained release of LH (and FSH) from
the pituitary that effectively induces oocyte maturation
and ovulation. A possible advantage of a GnRH agonist
for trigger in comparison with hCG is the simultaneous
induction of a FSH surge comparable to the surge of a
natural cycle [82]. GnRH agonist triggering, however, re-
sults in a shorter endogenous LH surge that leads to a de-
fective corpus luteum formation and an inadequate luteal
phase [83,84]. The profound luteolysis observed after
GnRH agonist triggering in contrast to the prolonged
luteotropic effect often seen after triggering with hCG has
been shown to almost completely eliminate the risk of
OHSS in high responders, avoiding the need for cycle
cancellation [82,85]. Because of the inadequate luteal
phase after GnRH agonist trigger, the use of standard
luteal phase support is inadequate and results in lower
conception and higher miscarriage rates [86]. Therefore,
luteal support strategies including one bolus of low-dose
hCG, repeated boluses of hCG, recombinant LH add-back,
and more intensive estradiol and progesterone supplemen-
tation were proposed to achieve optimal conception rates
[82,87-89].
Engmann et al. [87] showed that this approach was ef-
fective in a clinical study in which 66 patients at high risk
for developing OHSS were randomized to an ovarian
stimulation protocol consisting of either a GnRH agonist
trigger after co-treatment with ganirelix or a control group
that received hCG trigger after dual pituitary suppression
with birth control pills and a GnRH agonist. None of the
patients receiving ganirelix developed OHSS compared
with 31% of the patients in the control group. The study
also found no significant differences in the rates of im-
plantation (36.0% with ganirelix vs 31.0% with control),
clinical pregnancy (56.7% vs 51.7%), and ongoing preg-
nancy (53.3% vs 48.3%). In concluding, the authors sug-
gested that a protocol consisting of a GnRH agonist trigger
after GnRH antagonist co-treatment combined with luteal
phase and early pregnancy estradiol and progesterone sup-
plementation should be given strong consideration for
patients at high risk of developing OHSS.
In a more recent publication reviewing the predictive
factors of successful outcome after GnRH agonist trigger
and intensive luteal support, Kummer et al. [90] identi-
fied serum LH on the day of trigger and peak estradiol
levels ≥4000 pg/ml as the most important predictors of
success. Women with peak estradiol ≥4000 pg/ml had a
significantly higher clinical pregnancy rate than women
with peak estradiol <4000 pg/ml after GnRH agonist
trigger (53.6% vs 38.1%) [90]. The same group of investi-
gators subsequently reported that a dual trigger of final
oocyte maturation with a GnRH agonist and low-dosehCG (1000 IU) resulted in improved implantation, clin-
ical pregnancy, and live birth rates compared with a
GnRH agonist alone, without increasing the risk of clin-
ically significant OHSS in patients with peak estradiol
levels <4000 pg/ml [91].
Griesinger et al. [92] investigated the effect of cryo-
preservation of all two pronuclei-stage zygotes following
GnRH agonist trigger on the incidence of severe OHSS
and ongoing pregnancy rate in a prospective, observa-
tional, proof-of-concept study. The ongoing pregnancy
rate was 36.8% (95% confidence interval 19.1–59.0). No
patients developed moderate or severe OHSS [92].
LH add-back
Despite the advantages of GnRH antagonists—that is,
much shorter treatment regimens, fewer injections, and
the need for less gonadotropin—the more general accept-
ance of antagonist regimens has been hampered by their
perceived association with slightly lower pregnancy and
implantation rates compared with GnRH agonist protocols.
Results from early studies suggested that low implant-
ation rates were due to high daily doses of GnRH antag-
onists (0.5, 1, or 2 mg once daily) inducing a sharp
decrease in serum LH concentrations during the follicu-
lar phase of ovarian stimulation [93,94]. Supplementa-
tion with exogenous recombinant human LH (rLH) was
suggested as an alternative to counter the consequences
of LH depletion. In an RCT that included 60 patients,
Garcia-Velasco et al. [95] employed an innovative proto-
col in which the pituitary response was suppressed with
high-dose GnRH antagonist and rLH was added back to
correct the diminished implantation rate. GnRH an-
tagonist treatment (2 mg/d) was initiated on day 6 of
stimulation together with 375 IU rLH, and maintained
until the day of hCG administration, while control sub-
jects received the standard dose of 0.25 mg/d. Fluctuat-
ing LH concentrations were present on days 3 and 6 in
both groups. This fluctuation continued on day 8 and on
the day of hCG administration in the control (low-dose)
group, where 30% of patients had LH concentrations
<1 IU/L on the hCG day. The study (high-dose) group
showed stable LH concentrations on day 8 and on the
hCG day, with no LH surges. No clinical differences in
outcomes were found between the treatment groups.
The LH add-back strategy (375 IU/d) appeared to “res-
cue” the adverse effects that high doses of GnRH antag-
onist have been seen to impose on implantation.
More recently, Bosch et al. [96] assessed the impact of
LH add-back on cycle outcome during ovarian stimula-
tion with GnRH antagonists in an RCT performed in
two age subgroups ≤35 years (n = 380) and 36–39 years
(n = 340). rLH administration significantly increased the
implantation rate in the older population, and a clinically
relevant (although not statistically significant) better
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ingly, no benefit from rLH administration was demon-
strated in patients younger than 36 years.Use with and without oral contraceptives
Oral contraceptive pill pretreatment in GnRH antagonist
cycles has been advocated for scheduling ovarian stimula-
tion and oocyte retrieval in IVF programs. An RCT, by
Rombauts et al. [97], assessed the impact of oral contra-
ceptive scheduling with a ganirelix regimen on the ovarian
response of women undergoing rFSH stimulation for IVF,
compared with a nonscheduled ganirelix regimen and a
long GnRH agonist (nafarelin) protocol. The study found
that in the three groups the number of oocytes retrieved
and the number of good-quality embryos were similar.
Evidence from several other RCTs in the literature sup-
ports the use of oral contraceptive scheduling and shows
that success rates are the same [98,99], although it has
been found that after oral contraceptive pretreatment it
may take an extra day to stimulate [100]. In the most
recent Cochrane review, a subgroup analysis of 10 RCTs
that used oral contraceptives pretreatment showed that
there were no significant differences in ongoing pregnancy
rates in GnRH antagonist protocols compared with GnRH
agonist protocols [45].
Conversely, Griesinger et al. [101] showed a statistically
significant reduction in the likelihood of ongoing pregnancy
with oral contraceptive pretreatment when a pill-free inter-
val of 2–5 days is used before starting gonadotropin stimu-
lation in a meta-analysis of six RCTs on oral contraceptive
pretreatment in GnRH antagonist IVF cycles involving
1343 patients. The negative effect of the oral contraceptive
pretreatment on the IVF outcome may be explained by the
fact that some of the studies included in the meta-analysis
[101] started ovarian stimulation 2–3 days after the last oral
contraceptive pill rather than 5 days later.
More research is needed to determine the most reli-
able and efficacious way to schedule GnRH antagonist
stimulation cycles with oral contraceptive pretreatment.Use with and without estrogen pretreatment
Estrogen pretreatment in GnRH antagonist cycles has also
been suggested as an alternative method to achieve gonado-
tropin suppression during the early follicular phase so that
scheduling ovarian stimulation and oocyte retrieval in IVF
programs can be planned. Guivarc’h-Levêque et al. [102]
found that estrogen pretreatment was safe in a large pro-
spective study of patients undergoing IVF/ICSI. A greater
requirement of FSH and a longer duration of stimulation
were associated with estrogen pretreatment [103,104].
However estrogen pretreatment did not affect the IVF/ICSI
outcomes [103].Decreasing OHSS with GnRH antagonists
OHSS is a preventable condition and implementing
evidence-based prevention strategies should enable clini-
cians to reduce its occurrence. As we have discussed,
GnRH antagonist protocols and the use of a GnRH agon-
ist to trigger final oocyte maturation in a GnRH antagonist
protocol are two treatment strategies that could reduce or
prevent OHSS, especially when used in conjunction.
Significantly elevated or rapidly rising serum estradiol
concentrations are known to predispose patients to de-
velopment of OHSS. Therefore, since GnRH antagonist
treatment is associated with reduced estradiol concentra-
tions, it might be expected to decrease the risk of OHSS
[105]. Gustofson et al. [105] showed that ganirelix treat-
ment rapidly reduced circulating estradiol concentrations
without adversely affecting oocyte maturation, fertilization
rates, or embryo quality and resulted in a high pregnancy
rate in the subgroup of women with ovarian hyper-
response who were pretreated with a GnRH agonist. Des-
pite the treatment cohort being at high risk of developing
OHSS, only two cases of severe OHSS occurred. The RCT
by Lainas et al. [106] provided further evidence to support
the use of GnRH antagonists among patients at risk of
OHSS. This study compared a flexible GnRH antagonist
protocol with the long GnRH agonist down-regulation
protocol in 220 patients with polycystic ovary syndrome
(PCOS). While pregnancy rates were similar in the two
protocols, the GnRH antagonist protocol was associated
with a significantly lower incidence of OHSS.
The reduction in the incidence of OHSS with GnRH an-
tagonist protocols was shown in the Cochrane review of 27
RCTs in 2006 [107] and 29 RCTs in 2011 [45]. These sys-
tematic reviews compared GnRH antagonists (ganirelix or
cetrorelix) with the long protocol of GnRH agonist. A sta-
tistically significant reduction in the incidence of severe
OHSS with the antagonist protocol (27 RCTs: relative risk
ratio, 0.61; 95% confidence interval, 0.42–0.89; P = 0.01
[107]; 29 RCTs: odds ratio 0.43, 95% confidence interval
0.33–0.57 [45]) was observed. In addition, interventions to
prevent OHSS, such as coasting and cycle cancellation,
were administered more frequently in the agonist group
(27 RCTs: odds ratio, 0.44; 95% confidence interval, 0.21–
0.93; P = 0.03 [107]; 29 RCTs: odds ratio, 0.50, 95% confi-
dence interval, 0.33–0.76; P = 0.001 [45]). In a meta-
analysis of 7 RCTs, Xiao et al. [108] showed that the rate of
OHSS was significantly lower in the GnRH antagonist
group than the GnRH agonist group in women with PCOS
(odds ratio 0.36, 95% confidence interval 0.25–0.52).
Alternatively, the risk of OHSS can be reduced by trig-
gering final oocyte maturation with a GnRH agonist.
The reduction of the risk of OHSS using a GnRH agon-
ist trigger has been discussed above.
Another new method of tertiary prevention of early-
onset OHSS using GnRH antagonists has been reported
Table 2 Suitable candidates for GnRH antagonist
treatment
Patient populations benefiting from GnRH antagonist protocols
• Patients undergoing first-line controlled ovarian stimulation [8,59]
• Patients who have not responded to other controlled ovarian
stimulation regimens, including those with gonadotropin-releasing
hormone agonist [113]
• Patients with a poor prognosis [12]
• Oocyte donors [17]
• Patients at risk for ovarian hyperstimulation syndrome [93,105]
• Patients with polycystic ovarian syndrome [114]
• Patients taking oral contraceptive to regulate menstrual cycles [97]
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was re-initiated at a daily dose of 0.25 mg after patients
developed early OHSS, and continued daily for a week,
while all embryos were cryopreserved. No progression of
severe early OHSS was observed in any of the patients and
none of the patients required hospitalization.
Neonatal outcomes
Long-term outcomes after GnRH antagonist treatment do
not differ from those observed with GnRH agonist regi-
mens. Obstetrical and neonatal data on 839 pregnancies,
resulting in 969 live-born infants after ganirelix treatment
were compared with a historical cohort of 753 pregnancies
after long GnRH agonist (buserelin) treatment, resulting in
963 live-born infants [110]. There were no differences in
maternal characteristics, fertilization method, and preg-
nancy and delivery complications between the ganirelix
and historical GnRH agonist groups. Women experienced
more multiple pregnancies in the historical GnRH agonist
group (31.9%) than the ganirelix group (18.7%; P < 0.0001),
and both groups were comparable with respect to preg-
nancy loss after 16 weeks’ gestation. The incidence of
major congenital malformations in fetuses with gestational
age ≥26 weeks was 5.0% in the ganirelix cohort versus 5.4%
in the historical GnRH agonist group (odds ratio, 0.94; 95%
confidence interval, 0.62–1.42).
Boerrigter et al. [111] conducted a pooled analysis of
all follow-up data of the phase 2 and 3 trials for the de-
velopment of ganirelix. Data on 340 ongoing pregnancies
and neonatal outcomes for 432 children showed that
there were no differences between the GnRH antagonist
and GnRH agonist regimens with respect to pregnancy
loss after 16 weeks’ gestation, and the incidence and na-
ture of complications during pregnancy and delivery did
not differ between the two groups [111]. No major dif-
ferences were observed in neonatal characteristics of in-
fants in the ganirelix and agonist groups, who had an
overall mean birth weight on average of 3200 g for sin-
gletons, 2300 g for twins, and 1800–1900 g for triplets.
Congenital malformations were observed in 32 of 424
(7.5%) fetuses in the ganirelix group and in 10 of 181
(5.5%) in the agonist group.
Conclusions
We reviewed the scientific literature on the use of GnRH
antagonists, concentrating on the most recently available
evidence. Antagonist treatment protocols are a viable al-
ternative to agonist treatment. The multiple-dose protocol
is effective in the prevention of premature LH surge.
Compared with the long agonist protocol, GnRH antagon-
ist treatment is shorter, rapidly absorbed, rapidly revers-
ible, requires fewer injections, and appears to require a
lower amount of gonadotropins, which is likely to lead to
improved patient compliance and lower costs. The lowerpregnancy rate reported in some early RCTs has been off-
set by the findings of subsequent meta-analyses, and this
is probably the result of optimization of the antagonist
treatment protocol. The only contraindications to the use
of GnRH antagonists for the inhibition of premature LH
surges in women undergoing controlled ovarian stimula-
tion are hypersensitivity to GnRH antagonists or preg-
nancy [112]. GnRH antagonists have been used safely and
effectively in a wide range of patients (Table 2), such as
those undergoing first-line controlled ovarian stimulation
[8], those with a poor prognosis [12], and patients taking
oral contraceptives to regulate menstrual cycles [97]. The
antagonist flexible-dosing regimen has also shown prom-
ise among women diagnosed with PCOS [114]. Certain
other patient populations might particularly benefit from
ganirelix protocols, such as patients who have not
responded to other controlled ovarian hyperstimulation
regimens (including those with GnRH agonist) [113] or, to
the other extreme, patients with a high risk of developing
OHSS [93,105]. There are no adverse effects associated
with a GnRH antagonist protocol on assisted reproductive
technology outcomes. Due to the ability to trigger final oo-
cyte maturation with a GnRH agonist to prevent OHSS,
antagonist protocols are becoming the treatment of choice
for ovarian stimulation of oocyte donors [17].
Overall, GnRH antagonist treatment protocols are ef-
fective, easy to use, allow flexibility of treatment and,
therefore, appear to offer a promising alternative to the
long-established GnRH agonist regimens for prevention
of a premature LH surge during ovarian stimulation for
assisted reproductive techniques.
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